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Abstract: The rationale and technique underlying a novel concept of noninvasive fertility 
control by a new Cuproferrogel contraceptive drug, iron oxide–copper–styrene maleic 
anhydride–dimethyl sulphoxide (Fe3O4–Cu–SMA–DMSO) composite named ‘Smart RISUG’ 
(smart reversible inhibition of sperm under guidance) in presence of pulsed magnetic ﬁ  eld 
(PMF; 1 mT to 800 mT) is explained. It was synthesized by dispersing iron oxide particles and 
copper particles into SMA-DMSO (male contraceptive RISUG) and characterized for particle 
distribution, particle size measurement and transmittance peaks, etc. Interaction of the RISUG 
particles as well as Smart RISUG particles with Albino rat sperm cell was studied in presence 
as well as absence of PMF. To ﬁ  nd an explanation to increased reaching of the Smart RISUG 
drug into sperm under inﬂ  uence of magnetic ﬁ  eld, the transport properties were characterized by 
high resolution transmission electron microscopy and atomic force microscopy. Smart RISUG 
could be mobilized into sperm cell membrane at the PMF, 760 mT in about 50 seconds. Adoption 
of novel drug Smart RISUG involving new technique may open the pathway for non surgical 
control of drug distribution, detection and restoration of the normal fertility after removal of the 
contraceptive from the male/female reproductive tube in presence of electromagnetic ﬁ  eld.
Keywords: smart RISUG, pulsed magnetic ﬁ  eld, noninvasive fertility control, drug distribution, 
sperm cell
Introduction
Long acting and reversible fertility control still remains a challenge for the scientiﬁ  c 
community. Various contraceptive methods, including the use of hormone medications, 
intrauterine contraceptive devices, barrier contraception, periods of abstaining from 
sex, and surgery have been developed over the last few decades to prevent fertilization. 
Yet contraception failure and user dissatisfaction is not decreasing.1 An underlying 
reason for these limitations is that in time the state, both qualitatively and quantitatively, 
of the drug or device placed inside the body cannot be assessed noninvasively. The 
medical personnel are therefore not able to give advice regarding the likely period 
of contraceptive efﬁ  cacy. Additionally after implantation, the contraceptive agents 
cannot be controlled and inactivated in a programmed manner from outside the body 
to restore fertility on the user’s demand.
Reversible inhibition of sperm under guidance (RISUG) is an injectable male 
contraceptive of polyelectrolytic nature currently undergoing extended Phase III 
clinical trial.2 It consists of a hydrogel preparation of copolymer styrene maleic 
anhydride (SMA) dissolved in dimethyl sulphoxide (DMSO) possessing antimicrobial 
properties.3,4 Long-term vas occlusion with RISUG (SMA-DMSO) has been proved 
safe5–9 and effective.10–13 Reversal by injection of sodium bicarbonate solution as 
solvent has been demonstrated in the rat.14 Noninvasive reversal of SMA after a short 
period of implantation is also possible,5,6,15,16 but the noninvasive reversal method after 
extended period following the RISUG injection is not yet proven. Therefore although International Journal of Nanomedicine 2009:4 56
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RISUG is an advance in male contraceptive technology, its 
inadequate detection properties in imaging and external to 
the body control calls for the development of an improved 
contraceptive.
Smart RISUG, the new implant device described in the 
present paper, is seen in in vitro and rat in vivo studies to 
give better spermicidal action than RISUG.17 Also comprising 
of iron oxide–copper–styrene maleic anhydride–dimethyl 
sulphoxide (Fe3O4–Cu–SMA–DMSO) the implant is 
detectable by X-ray and magnetic imaging and in vivo 
distribution can be controlled by the application from outside 
the body with an external pulsed magnetic ﬁ  eld (PMF).18 
The Smart RISUG implant design targets to overcome the 
two major limitations of RISUG that pertain to control and 
detection.
The underlying science behind Smart RISUG links with 
magnetics and polymer science. One phenomena drawn 
upon for the in vivo control of Smart RISUG is the change 
of the elasticity of a ferromagnetic polymeric compound 
with magnetization.19 It is known that both the concentration 
of magnetite particles and the cross-linking density of 
the ferrogels play an essential role in the magnetoelastic 
behavior.20 Raikher and Stolbov21 discussed elongation of 
a magnetoelastic material under the action of a uniform 
external magnetic ﬁ  eld.
A time-varying external magnetic ﬁ  eld programmed to 
alter directions induces directional elasticity variations in a 
magnetic ferrogel implant and provides a means of control of 
mechanical properties. There is a concurrent magnetic effect 
too. When a magnetic ﬁ  eld is applied, a ferrogel acquires a net 
magnetic moment due to the ordered orientation of particles 
in the ﬁ  eld direction. This magnetic ordering is reversible. 
The material reverts to randomized orientation on switching 
off the external ﬁ  eld.22 Several approaches can be adopted to 
take advantage of this property for contraceptive distribution 
and control. In one technique, a steady magnetic ﬁ  eld leads 
to orientation and magnetic moment generation and a crossed 
time-varying ﬁ  eld produces micro rotations of the magnetic 
entities and in consequence of the bulk polymeric material. 
These micro motions embed the contraceptive into the tissue 
fold in the lumen of the reproductive tract mucosa helping 
in long term retention of the compound.
Nanomicro-sized magnetic particles when in use for 
fertility control tend to agglomerate and adsorb to plasma 
proteins due to their large surface-to-volume ratio and 
magnetic properties.23 Therefore, surface coverage of 
magnetic particles Fe3O4 with a safe and effective polymer 
SMA signiﬁ  cantly increases the stability and ensures proper 
distribution by eliminating agglomeration and adsorption 
to proteins.24–26 In line with Hoffman and colleagues’27 
observation that PVA coating of superparamagnetic iron 
oxide nanoparticles (PVA-SPION) reduced the cytotoxic-
ity of native iron oxide to synovial cells of sheep melanoma 
cells, it is theoretically predictable that SMA coating of iron 
oxide will have no cytotoxic potential on of the iron oxide 
component.
Copper particles in the contraceptive introduce 
two functions. Copper, with its intrinsic high electrical 
conductivity, makes the overall compound electrically 
conductive in contrast to the purely polymeric RISUG 
which is a poor electrical conductor. Electromagnetic 
induction heating of the implant by means of an external 
microwave ﬁ  eld is feasible. By heating, the contraceptive 
can be softened to facilitate removal for restoration of 
fertility. The second function of copper is to displace some 
speciﬁ  c molecules, for example, zinc, from the sperm 
membrane thereby lowering the fertilizing potential of the 
sperm. Copper lowers the fertility of ovum by displacement 
of proteins.28 Hence the presence of copper enhances the 
contraceptive action of Smart RISUG in both the male and 
female applications.
Extensive literature in the ﬁ  eld reports a number of 
nanotech ferromagnetic compounds. These materials were 
synthesized for both biological and nonbiological uses. 
A review indicates that the properties do not match with 
the needs of fertility control; in particular a drug which 
can be implanted and controlled from outside the body by 
means of PMF. Although the spermicidal and tissue reaction 
properties of these materials have not been reported, a 
review of the basic chemical structure indicates that the 
compounds described in scientiﬁ  c literature would not have 
the desired combination of high spermicidal action together 
with low adverse tissue reaction. Efﬁ  cacy as a spermicide 
has not been investigated. A close examination of the 
chemical structure suggests that the combination of desired 
properties will not be delivered by these products. Therefore 
the main objectives of our present research were to structure 
Smart RISUG and determine the feasibility of noninvasive 
control and to target this new drug into rat sperm cell 
membrane with the help of an impulse magnetizer. The 
physicochemical properties of this new compound were 
analyzed by differential scanning calorimetry (DSC); 
Fourier transform infrared spectroscopy (FTIR); high 
resolution X-ray diffractometery (HR-XRD); energy 
dispersive X-ray spectroscopy (EDS); and high resolution 
transmission electron microscopy (HRTEM).International Journal of Nanomedicine 2009:4 57
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Materials and methods
Materials
Sourcing of the raw materials used in the study was: SMA 
from the RISUG Pilot Plant (Indian Institute of Technology, 
Kharagpur, India); Fe3O4 (Eisen (III) oxid, pulver   5 micron, 
98%) made by Sigma-Aldrich (GmbH, Germany). Cat.; 31, 
006–9 make; copper powder – 625 mesh, APS 1–1.5 micron, 
99% (metals basis) obtained from Alfa Aesar (Shore Road, 
Heysham, Lancaster, UK); dimethyl sulphoxide (DMSO 
D2650, HYBRI-MAX®, hygroscopic, FW 78.13) supplied 
by Sigma-Aldrich (Singapore); glutaraldehyde solution 
2.5% purchased from Merck CAS No. 111-30-8; phosphate 
buffer saline (PBS) procured from Merck (Darmstadt, 
Germany); ethanol, absolute (CH3-CH2-OH, AR, MW 
46.080) purchased from Hong Yang Chemical Corporation 
(China); osmic acid 2% solution w/v for microscopy was 
obtained from ISO 9001–2000 certified CDH (P) Ltd. 
(New Delhi, India); araldite 506 epoxy resin, viscosity 
(25 °C): 500–700 cps, weight per epoxide: 172–185 was 
also purchased from Sigma-Aldrich (St. Louis, MO, USA); 
uranyl acetate and lead (II) citrate trihydrate for electron 
microscopy, Fluka grade, Mr1053.83 from Sigma Aldrich 
(UK); propidium iodide (PI) solution 1.0 MG/ML, P4864, 
FW 668.4 used for ﬂ  uorescent staining purpose imported 
from Sigma-Aldrich (USA).
Preparation of Smart RISUG compound
SMA copolymer was synthesized as per the protocol given 
by the inventor mentioned in US patent 5,488,075.4 The new 
Cuproferrogel compound Fe3O4–Cu–SMA–DMSO or Smart 
RISUG was synthesized by adding 2%–15% (w/v) iron oxide 
nanomicro-sized particles ( 5 μm), 3%–8% (w/v) copper 
nanomicro-sized particles and SMA together to the DMSO 
(1:8) under a dry XL grade nitrogen atmosphere. The nitrogen 
gas was ﬁ  rst passed through a 0.2 μ ﬁ  lter. Thereafter, the 
solution obtained was continuously stirred for 48 hours at 
35 °C adopting the method given by the inventor.18
Animal maintenance
With the approval of the Institutional Animal Ethics Committee, 
mature male albino rats of weight   150 g were used for 
this experiment. Albino rats kept at the animal house of the 
Department of Biotechnology, Indian Institute of Technology, 
Kharagpur, India under condition as per recommendations of 
the Institutional Animal Subject Review Committee. Animals 
were maintained at approximately 25 °C and 55% humidity 
with a 12 hr light–12 hr dark cycle and were with standard 
chow and water ad libitium.
Sperm cell collection
Sperm cells were collected from the distal cauda epididymis 
of mature male albino rats, (weighing 150–200 g) after 
anesthetizing the animals with sodium barbiturate i.p. 
(30 mg/kg). About 1 cm stream of epididymal ﬂ  uid was 
expelled from the cauda into 3 ml of 0.1 M PBS (pH 7.4) in a 
35 mm polystyrene culture disk.29 The epididymal tissue was 
removed and the dish kept in incubator for 10 minutes. Sperm 
samples were then diluted to about 15–20 × 106 sperms/ml. 
The viable cells were collected by swim-up technique.30
Sperm count, motility and viability
Microscopic examination of the slides of sperm cells after 
interaction with RISUG and Smart RISUG at magnetic 
ﬁ  eld of different pulse densities followed. A Neubauer cell 
counting chamber served as the calibrated grid for sperm 
counts. Sperm motility was assessed by a phase contrast 
microscope (Olympus CKX41 Optical Co., Shizuoka, Tokyo, 
Japan) equipped with a 40 × objective and a Steves Digicams 
C-5060 wide zoom camera.
Energy dispersive X-ray spectroscopy
Smart RISUG is a chemically cross-linked Cuproferrogel, a 
colloidal dispersion of magnetic particles having superpara-
magnetic behavior and copper. Preferred particle form is a 
size less than 5 μ diameter and being a mix of nano-sized 
and micro-sized Fe3O4 and Cu particles. EDS associated 
with X-ray microanalysis of the new compound was done 
with scanning microscope. (JEOL JSM-5800, OXFORD 
ISIS-300, NY, USA)
Particle size analysis
The particles size of iron oxide and the new drug Smart 
RISUG were observed with the particle size analyzer (MAL-
VERN Instruments, Zetasizer nano ZS, Worcestershire, UK).
Fourier transform infrared spectroscopy
FTIR analysis of the RISUG and the new compound Smart 
RISUG was done with FTIR instruments, Thermo Nicolet 
NEXUS 870 Corporation, Brewster, New York, USA.
High resolution transmission 
electron microscopy
HRTEM studies were performed on a transmission 
microscope. (Model JEM 2100 Oxford Instruments, 
Oxfordshire, UK) High magniﬁ  cations, bright ﬁ  eld imaging, 
selected area electron diffraction (SAED) were performed 
on JEM 2100.International Journal of Nanomedicine 2009:4 58
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Atomic force microscopy
Fixed sperm cells were immobilized on 0.01% poly-L-lysine-
coated slides prior to analysis by noncontact mode atomic 
force microscopy (AFM; Thermo Microscopes, CP Research 
Model, and Sunnyvale, CA, USA). Control and Smart 
RISUG-treated samples were analyzed for changes by 
tapping mode AFM on the outer surface of sperms. A 50 μ 
long silicon cantilever, with a force constant of 17.2 N/m 
was vibrated near its resonance frequency of 320 kHz. The 
deviation of the vibration frequency from resonance depends 
on the tip-sample preparation and forms the data set providing 
the topography of the sperm cell.
External pulsed magnetic ﬁ  eld 
exposure system
A laboratory designed and fabricated impulse magnetizer 
of up to 800 mT ﬁ  eld strength provided variable magnitude 
magnetic pulses for the investigations. This instrument 
basically consists of 2000 μF capacitor bank charged to a 
voltage of 50 kV by means of a high-turn ratio transformer 
and rectiﬁ  er. The capacitor charge was switched on to a very 
low electrical resistance copper coil to generate the magnetic 
ﬁ  eld. Field strength produced was monitored with a search 
coil connected to a 100 MHz recording oscilloscope. Before 
commencing the experiment, freshly collected sperm sample 
was kept inside a test tube in front of the magnetic coil. On 
discharging the instrument, magnetic ﬁ  eld of a speciﬁ  c pulse 
was produced depending on the rate of magnetization of the 
magnetic coil. The range of magnetic ﬂ  ux density produced 
by the instrument is 1 mT (with main spectral band centered 
at 50 Hz to 800 mT with centre frequency of 40 KHz. The 
magnetophoretic mobility of the compound was measured 
manually by observing the distance moved in time. Ingress 
of the Smart RISUG compound into sperm cell was observed 
with microscope and the speciﬁ  c pulse produced each time 
was calculated with oscilloscope as per the calibration of the 
magnetic search coil.
Magnetophoretic mobility
Magnetic ﬁ  eld-mediated transport properties of the Smart 
RISUG compound are dependent on the magnetophoretic 
mobility which is a measure of cell magnetism that is 
magnetic force per bead (Fb) and represented by
  Fb = Δ χb. Vb. Sm  (1)
where χb = volumetric magnetic susceptibility of magnetic 
bead; Vb = volume of magnetic particle; Sm = quadrupole 
magnetic ﬁ  eld strength/magnetic energy density. Magnetic 
force on each cell (Fm) is
  Fm = ABC. β . Fb = (n1 θ1 λ1) (n2 θ2 λ2) (2)
where β = amplification factor (no of magnetic beads 
attached); n1 = no of coating particles (here RISUG); 
λ1 = fraction of coating particles (here RISUG); λ1 = valency 
of binding particle (here RISUG); n2 = no of magnetic 
particles (here Iron oxide); λ2 = fraction of magnetic particles 
(here Iron oxide); λ2 = valency of central particle (here Iron 
oxide). Therefore, drag force on each cell (Fd) is
  Fd = (3π . Dc. η). Uc  (3)
where Dc = diameter of cell; η = viscosity of the medium; 
Uc = induced velocity in the ﬁ  eld.
Statistical analysis
Student’s paired t-test was used to measure the difference 
between the samples. P   0.5 was considered statistically 
significant. All values are given as mean ± standard 
deviation (SD).
Results
A. Smart RISUG co-polymer drug 
synthesis and characterization
Particle distribution
Energy dispersive X-ray microanalysis (EDS) investigated 
arrangement of the Fe3O4–Cu–SMA–DMSO Cuproferrogel 
particles about 50 nm to 4 μ (Figure 1). An approximately 
uniform size of SMA–DMSO-coated iron oxide particles and 
copper particles were observed. The drug particles appeared 
to be properly dispersed.
Particle size analysis
Figure 2A shows that average size of Fe3O4 particles used 
here is 201.2 nm. Polydispersity index value (PI) of Smart 
RISUG (Figure 2B) after Cuproferrogel formation done with 
the particle size analyzer illustrates that the average size of 
Smart RISUG particles is 628.2 nm.
Transmittance peaks
FTIR peaks of the Fe3O4–Cu–SMA–DMSO (Smart RISUG) 
compound found at 952 cm−1, 1020 cm−1, 1317 cm−1, 
1650 cm−1, 2917 cm−1, etc. indicated presence of RISUG mol-
ecule in the ‘Smart RISUG’ (Figure 3B). In addition to parent 
constituents SMA and DMSO, the signiﬁ  cant peaks observed 
at 707 cm−1, 1436 cm−1 indicated presence of nanomicro International Journal of Nanomedicine 2009:4 59
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magnetic particles (Fe3O4) and 3004 cm−1 peak indicated 
presence of copper particle in the new compound.
External magnetic ﬁ  eld-mediated 
control and interaction of Smart 
RISUG with sperm cell
Transport mechanism
HRTEM showed that Smart RISUG particles which could 
enter sperm cell membrane were of 50 nm to 200 nm size, 
the range suitable for delivery in a reproductive tube as it 
neither enters the blood circulation nor gets away with the 
reproductive tube ﬂ  uid. Figure 4A shows attachment of new 
compound particles to the sperm cell membrane at head 
region. Figures 4B and 4C track Smart RISUG particles 
inside the sperm cell. It is evident that particles either attach 
to cell membrane or enters only nearby cytoplasm without 
causing damage to the genetic material. This point is of con-
siderable signiﬁ  cance in terms of safe genotoxic potential of 
the drug in clinical application.
Effect of external pulsed magnetic ﬁ  eld exposure 
on Smart RISUG compound
In physical magnetophoretic mobility experiments, the 
overall lengthening of the material kept in a test tube as 
a percentage of the pre PMF exposure length versus the 
magnetic ﬁ  eld strength is shown. The relative displacement 
induced by nonuniform magnetic ﬁ  eld can be 40% of the 
initial length (Figures 5A and 5B). The Smart RISUG drug 
mobility initiates above PMF of 80 mT. An abrupt increase in 
the lengthening in ﬁ  eld strength of about 280 mT provides a 
general guideline for the choice of optimal ﬁ  eld strengths for 
biophysical experiments. Thus a signiﬁ  cant magnetostriction 
took place and hysteresis was observed (Figure 5c). 
One other experiment was conducted to determine optimum 
concentration of iron oxide. Taking different concentration 
(2% to 15% by weight) of iron oxide particles in the new 
compound wherein the threshold magnetic ﬁ  eld for mobility 
for each concentration was estimated. It was observed that 
with increasing iron oxide concentration the threshold 
magnetic ﬁ  eld required for movement initiation decreases. 
Suitable concentration of the iron oxide was found to be 
8% to 12% by weight and threshold magnetic ﬁ  eld strength 
required for its lengthening initiation was found to be 80 mT 
(Figure 5D).
Interaction of sperm cell with Smart RISUG 
in the absence and presence of pulsed magnetic 
ﬁ  eld produced by the impulse magnetizer
RISUG precipitate when made to attach to top of the test 
tube, it could not be transported into sperm cells kept at 
the bottom of tube either in presence or absence of PMF. 
Similarly, no signiﬁ  cant change in the sperm count or sperm 
motility percentage occurred when Smart RISUG precipitate 
and diluted sperm cells are kept at the two ends of the test 
tube in the absence of PMF as in this case the Smart RISUG 
is not able to reach or enter the sperm cell membrane in order 
to facilitate any changes thereof.
Figure 1 X-ray microanalysis of the Fe3O4–Cu–SMA–DMSO (Smart RISUG) indicating 
arrangement of drug particles in the Cuproferrogel compound.
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In the present study no signiﬁ  cant variation in the sperm 
count and percentage of motile sperm were found when 
RISUG interacted with sperm cell either in presence or 
absence of PMF given for 30 s to 50 s. The new contraceptive 
molecule started moving at 80 mT but showed abrupt 
transformation at 280 mT only. Table 1 reveals that Smart 
RISUG achieved abrupt transformation at about 280 mT and 
it could be transported into sperm cell membrane at 760 mT 
only. The interaction of rat sperm with Smart RISUG caused 
30% decrease in sperm count and 70% decrease in sperm 
motility (p   0.05) (Table 1).
Drug-induced topological alteration
AFM image of untreated rat sperm cells (Figure 6A) gave 
evidence of smooth surface topography throughout the 
length of the sperm cell membrane. A cluster of sperm 
cells with prominent head were observed with AFM. In 
contrast, sperm cells treated with Smart RISUG (Figure 6B) 
gave disintegrated surface topology with a complete loss 
of smoothness. The three-dimensional AFM image of 
the same showed curved tail and damage to the middle 
piece. A signiﬁ  cant reduction in the cell height had been 
observed for treated sperm cells with AFM. An interesting 
observation here was the pattern of attachment of Smart 
RISUG particles to sperm cell membrane complimenting 
HRTEM observation.
Discussion
The present study reveals magnetic ﬁ  eld-directed Fe3O4–
Cu–SMA–DMSO Cuproferrogel drug interaction with 
sperm cells that may open new dimensions in the ﬁ  eld of 
biomagnetic technology. RISUG action on sperm cells is not 
altered by PMF. PMF in the ﬁ  eld strengths of 80–800 mT 
applied for 30 s to 50 s does not have signiﬁ  cant effect on 
the sperm. The change in the form of RISUG to that of Smart 
RISUG too does not alter the effect on sperm. That is, the 
concentrations of iron oxide and copper are sufﬁ  ciently low 
as not to affect sperm function by their presence. Only the 
combination of the iron oxide–copper–PMF enhances the 
spermicidal action and hence the contraceptive efﬁ  cacy of 
the parent RISUG compound. Moreover there is a threshold 
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iron oxide concentration above which the phenomena are 
manifest. Furthermore PMF of 760 mT or above is required 
to induce the spermicidal enhancement potential. The about 
30% decrease in the sperm count and about 70% decrease 
in the sperm motility percentage demonstrated in the present 
study imply that good contraceptive action may be realized 
with lower drug dose than the conventional RISUG.
HRTEM elucidates the entry mode of Smart RISUG 
particles into the sperm cell. Figures 4A and 4B illustrates 
that particles are not endocytosed by the sperm cells rather 
they attach to the sperm head surface or enters cytoplasm 
in vicinity of the sperm cell plasma membrane (Figure 4C) 
and thus inactivate the sperm cells. It is previously 
hypothesized that plasma membrane is directly involved 
in the mechanisms by which nonthermal extremely low 
frequency (ELF) electromagnetic ﬁ  elds exert their action 
on cell functions.31 Membrane disintegration of the sperm 
at the acrosomal region leads to leaching out of enzymes 
acrosin and hyaluronidase, thus rendering the sperm 
infertile, a mechanism similar to RISUG observed with 
AFM (Figure 6B).
Previous work on RISUG also reports that as sperm come 
into contact with the SMA–DMSO complex, the combina-
tion of positive and negative charges on the polymer surface 
causes the sperm membrane to burst.11 When co-polymer 
of styrene and maleic anhydride dissolved in DMSO was 
injected into the vas deferens of rats the morphological 
changes detected were conﬁ  ned to the mucosa.9 Just after 
injection, RISUG lowers the pH sufﬁ  ciently to kill the sperm 
passing through.32,33 RISUG is presently undergoing extended 
phase III clinical trials in India2,34 after successfully complet-
ing phase I and phase II trials.33,35–37 The presence of common 
parent component SMA in Smart RISUG ensures long-term 
safety and safe reversibility of the drug.
For Smart RISUG drug synthesis the SMA copolymer is 
dissolved in solvent medium DMSO. Thereafter, magnetic 
material Fe3O4 is added to the polymer to impart magnetic 
properties and copper is added to obtain electrical conductivity 
and charge transfer capability that in turn affect structure of 
sperm/ovum by displacing speciﬁ  c molecules. Here, Fe3O4 
added to SMA-DMSO facilitates noninvasive imaging as 
well as control of distribution of the drug in the reproductive 
tube under guidance of external magnetic ﬁ  eld by enhancing 
contrast of drug with the body tissue. Use of magnetic particle 
iron oxide in Smart RISUG exploit two major advantages; 
their low toxicity to human beings and the possibility to use 
their outstanding properties by allowing the high magnetiza-
tion of the iron oxide to target drugs to/from a speciﬁ  c cell 
through an external magnetic ﬁ  eld.38,39 The addition of copper 
particles displaces speciﬁ  c molecules like zinc from sperm 
cell, reduces sperm motility and increases sperm abnormality. 
Both additives are uniformly dispersed in the base polymer 
and aggregation is prevented by suitable coating with cross-
linked SMA and continuous stirring for 45–50 hrs.
The contraceptive preparation is taken in a 250 pl syringe 
provided with a 23 gauge needle for injection into male/
female reproductive tube. In male a puncture is made in 
anterior scrotum to elevate vas deferens and then the needle 
is inserted into vas lumen. Smart RISUG has properties 
of electrical charge producing, pH lowering, molecular 
exchange property, charge transfer property and residual 
magnetism. The drug after injection swells and invaginates 
into the folds of the lumen to help retention but does not 
adhere to the tissue. When the pure polymeric RISUG is 
injected into the vas deferens the sperms present in the vas 
deferens at the time of injection are subjected to RISUG 
action and break-up. The fragments of the sperm are voided 
at the time of ejaculation. If on the other hand a compound 
such as Smart RISUG is injected into the vas deferens and 
concurrently PMF is applied the iron oxide enters the sperm 
membrane. A mosaic architecture of iron oxide and with it 
copper micro-strands corresponding to the sperm shape are 
formed (Guha, Pers Comm). These micro-strands enveloped 
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lower end caused Cuproferrogel elongation. C) Smart RISUG deﬂ  ection ∆h/h0 (%) 
versus current (A) given –a hysteresis graph obtained (D) Threshold magnetic ﬁ  eld vs 
iron oxide concentration. The presence of 10% iron oxide causes threshold magnetic 
ﬁ  eld effect in presence of external magnetic ﬁ  eld.International Journal of Nanomedicine 2009:4 62
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by sperm proteins and lipids persist and create a large surface 
of electrical charge interaction for the destruction of sperms 
passing later on even without PMF. In this manner the 
spermicidal action is enhanced in a sustained manner. The 
removal as proposed in present paper is easily possible by 
using magnetic properties of the contraceptive to propel the 
drug for fertility restoration by external magnetic ﬁ  eld.
This study explains that the new contraceptive molecule 
Fe3O4–Cu–SMA–DMSO (Smart RISUG) starts moving as 
a system in the presence of external PMF. The magnetic 
ﬁ  eld exposure system developed for this study produced 
ﬂ  ux density up to 800 mT. As each particle is the elemen-
tary carrier of a magnetic moment, similar is the case for 
Smart RISUG particles that couple the shape of the gel to 
the PMF. On application of varying PMF, as the current of 
the electromagnet increases there is small movement of the 
new compound followed by an abrupt rise in the transport 
properties (Figure 5C). At the threshold magnetic field 
80 mT given for periods of 50 s, the Smart RISUG compound 
starts movement and at about 760 mT, 50 s, the compound 
A
B
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μm/div
5.0 μm/div
5.0 μm/div
5.0 μm/div
5.0 μm/div
0.058
0
0.041
0
Figure 6 Atomic force microscopy (AFM) images of rat sperm. A) 2D and 3D images of untreated cells showing cluster cells with smooth surface. B) 2D and 3D images of 
Fe3O4–Cu–SMA–DMSO (Smart RISUG) treated cells showing blabs in plasma membrane, disintegration leading to enzyme leaching, shortened height, and curved tail.International Journal of Nanomedicine 2009:4 63
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Table 1 Effect of external pulsed magnetic ﬁ  eld (PMF)-mediated Smart RISUG exposure on the sperm cell count and motility where 
respective drugs and sperm cells are kept at the two different ends of reproductive tube model for this noninvasive control experiment
Sperm cell 
count (106/ml)
Sperm cell 
motility (%)
1. C (absence of PMF) 25.05 ± 1.10 68.37 ± 3.97
2. C (presence of PMF) 24.89 ± 6.54 68.13 ± 2.89
3. RISUG (absence of PMF) 24.87 ± 1.13 67.90 ± 6.32
4. RISUG (presence of PMF) 24.32 ± 5.25 67.80 ± 4.66
5. Smart RISUG (absence of PMF) 24.87 ± 1.32 65.29 ± 2.24
6. Smart RISUG treated (presence of PMF) 17.74 ± 0.98 45.12 ± 4.13
Note: Data presents the mean ± SEM of ﬁ  ve samples (p   0.05).
Abbreviations: C, control; PMF, pulsed magnetic ﬁ  eld.
could enter the sperm cell membrane (Figure 4A). Transport 
occurs instantaneously and disappears abruptly when the 
external magnetic ﬁ  eld is removed.35%–45% lengthening 
of the Smart RISUG drug with respect to pre-PMF length 
could be produced by applying a nonuniform magnetic ﬁ  eld 
(Figure 5B).
EDS–X ray spectroscopy analysis observed the proper 
dispersion of Smart RISUG Cuproferrogel particles 
(Figure 1). FTIR analysis transmittance peaks of the 
Fe3O4–Cu–SMA–DMSO (Smart RISUG) found at 952 cm−1, 
1020 cm−1, 1317 cm−1, 1650 cm−1, and 2917 cm−1 indicates the 
presence of SMA–DMSO molecule in the ‘Smart RISUG’. 
In addition to these, the peaks at 707 cm−1, 1436 cm−1, and 
3004 cm−1 indicate that the nanomicro-sized Fe3O4 and 
Cu particles has been encapsulated by the SMA–DMSO 
molecule (Figures 3A, 3B).
Our experimental and theoretical studies indicated that 
in the absence of magnetic ﬁ  eld neither RISUG nor Smart 
RISUG is able to interact with the sperm cells. Signiﬁ  cant 
transport properties of Smart RISUG compound can only 
be observed when the applied magnetic ﬁ  eld is above the 
threshold value. Present fertility control technology of 
magnetic ﬁ  eld-mediated sperm interaction of the new con-
traceptive molecule Smart RISUG needs further study for 
any possible toxicity chances before applying this technol-
ogy to human subjects even though the moderate amount of 
Fe3O4 being used here does not affect sperm functionality.27,40 
However, initial studies of Smart RISUG on both gonad 
weight analysis and sperm anomaly assay proves in vivo 
safety and efﬁ  cacy of the new drug in rat.17 Present study 
suggest use of new drug Smart RISUG in order to facilitate 
better spermicidal action, control of distribution of the 
fertility control agent implanted inside the male or female 
reproductive tube and noninvasive detection by application 
of external magnetic ﬁ  eld.
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